AWM Investment Company Inc. Buys 135,000 Shares of Progyny, Inc. (NASDAQ:PGNY)

AWM Investment Company Inc. increased its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 540.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 160,000 shares of the company’s stock after purchasing an additional 135,000 shares during the period. AWM Investment Company Inc. owned 0.19% of Progyny worth $2,760,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in PGNY. Barclays PLC lifted its holdings in shares of Progyny by 530.4% in the third quarter. Barclays PLC now owns 706,157 shares of the company’s stock worth $11,835,000 after buying an additional 594,140 shares in the last quarter. Franklin Resources Inc. increased its holdings in Progyny by 17.0% during the 3rd quarter. Franklin Resources Inc. now owns 48,248 shares of the company’s stock worth $759,000 after acquiring an additional 7,003 shares during the period. Ballentine Partners LLC purchased a new stake in Progyny in the 4th quarter worth approximately $187,000. Clear Harbor Asset Management LLC bought a new position in Progyny in the 4th quarter valued at $989,000. Finally, Fort Washington Investment Advisors Inc. OH boosted its holdings in Progyny by 90.1% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock valued at $25,319,000 after purchasing an additional 695,740 shares during the period. Institutional investors own 94.93% of the company’s stock.

Progyny Stock Performance

Shares of PGNY opened at $21.87 on Wednesday. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $30.42. The firm has a 50 day moving average price of $22.15 and a 200-day moving average price of $19.85. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of 37.71, a PEG ratio of 2.39 and a beta of 1.37.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.28). The business had revenue of $324.04 million for the quarter, compared to analysts’ expectations of $307.86 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business’s quarterly revenue was up 16.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.17 earnings per share. As a group, equities research analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on PGNY shares. Canaccord Genuity Group decreased their price target on shares of Progyny from $23.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, May 12th. BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Monday, March 31st. JPMorgan Chase & Co. lifted their price target on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. Finally, Bank of America upped their price objective on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $23.45.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.